Racetam
Fasoracetam
A racetam compound explored for its potential effects on cognitive function, focus, and mood.
KÖGN Health grades Fasoracetam as C+ (Limited evidence) and rates it 3.6 out of 5.
Last reviewed · June 2026
Primary effects
- Improved focus
- Mood support
- Cognitive function
How it works
Modulates neurotransmitter systems including GABA and glutamate, influencing cognition and mood.
Overview
Fasoracetam has gained interest for its potential role in attention and mood regulation, particularly in experimental settings. However, human research is limited, and much of the evidence is preliminary. It is often used in niche or advanced nootropic stacks rather than as a foundational compound.
The evidence
Fasoracetam is a racetam that acts on glutamate (mGluR) and GABA systems, originally trialled for dementia (without clear success) and more recently explored for ADHD in children with specific glutamate-gene variants. Robust evidence in healthy adults is absent; it remains an investigational compound.
Safety & side effects
Limited human safety data outside the investigational trials; long-term effects are not characterised.
Who should avoid it
An unapproved, investigational research compound rather than a sanctioned supplement — quality, legality and long-term safety are uncertain. Avoid in pregnancy and discuss with a clinician. Evidence in healthy people is essentially absent.
References
Related ingredients
Graded entries that target the same cognitive goals.
Categories
Draft — the dose, safety and evidence notes on this entry were prepared from the published literature and are pending editorial and clinical review.
Educational information, not medical advice. The evidence grade is KÖGN’s editorial assessment of published research, not a health claim. Speak to a qualified clinician before changing what you take.